The abstract is read at the publisher; the summary is JClub's.
Facilitated cascade genetic testing increased 6-month uptake among adult first-degree relatives of BRCA1/BRCA2 pathogenic-variant probands to 73.2% versus 50.7% under standard care.
- Why it matters: Many at-risk relatives do not complete cascade genetic testing, limiting the public health impact of identifying hereditary cancer risk.
- What they did: In a cluster-randomized trial, probands were assigned to facilitated navigation plus testing access or standard care letters; 142 and 144 eligible adult first-degree relatives were enrolled, with free testing for all.
- The result: At 18 months, 90% of intervention relatives completed testing, and among 206 tested relatives, 46% had a pathogenic or likely pathogenic variant, with 86% carrying the familial variant.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.